Scientific Content

Management of ALLERGIC FUNGAL RHINOSINUSITIS (AFRS): A sever type 2 Inflammatory Disease

The management of AFRS remains challenging to reduce disease burden and limit potential structural damage complications

GvHD in Focus Risk Factors and Symptoms

This educational video highlights chronic Graft‑versus‑Host Disease (cGvHD), a long‑term complication following allogeneic stem cell transplantation. It outlines key risk factors for cGVHD and demonstrates common clinical manifestations affecting skin, eyes, mouth, lungs, joints, GI tract, scalp, liver, and Fascia. The video emphasizes early recognition to support timely management and improved long‑term outcomes.

Real-World Effectiveness of Nirsevimab: Evidence from the NIRSE-GAL Study

The NIRSE-GAL study is an ongoing population-based, prospective, longitudinal study conducted in Galicia, Spain. It includes infants eligible to receive nirsevimab and evaluates its impact on RSV-related outcomes in both inpatient and outpatient healthcare settings.

Guidelines for RSV prevention with Nirsevimab

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections in infants and young children. Nirsevimab is a long-acting monoclonal antibody that provides passive immunization against RSV, offering protection throughout the RSV season with a single dose

RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

This video explains WEQAYA's strategy on Nirsevimab Implementation

An easy guide to use Nirsevimab

ADCT – Atopic Dermatitis Control Tool

Pre-Ramadan assessment and Risk calculation for people with diabetes who want to fast during Ramadan

Rare Disease Academy 2.0/ Spotting the Signs: A guide to Early Diagnosis and a Timely Refferals

Spot early signs of Pompe, Gaucher, Fabry, ASMD & MPS I. A Sanofi guide to early diagnosis and timely referrals for rare lysosomal storage disorders.

MS pulse - Tracking the hidden drivers of MS progression

Advancing the Standard of Care: Addressing Progression in MS

An evidence-based exploration of the current MS landscape, focusing on the pathophysiology of Progression Independent of Relapse Activity (PIRA). This module examines the clinical significance of disability accumulation and the remaining unmet needs in long-term patient management.